'We were wrong': After ushering Merck KGaA into PD-(L)1 frenzy, oncology chief jumps on mission to 'turbocharge' T cells
Zhen Su’s love for T cells — which he compares to his high school sweetheart — began long before he took over the oncology development group at Merck KGaA.
But it was at the German pharma giant that he oversaw the development of Bavencio, its candidate in the heated PD-(L)1 race that pretty much defined his six-year tenure. That front row seat gave Su a close-up view of checkpoint inhibitors and its limitations: Some of them work too slowly; when they do, they only help a third of all patients at most; and not all have proven durable.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,400+ biopharma pros reading Endpoints daily — and it's free.